Raadpleeg ook literatuurlijsten niet-toxische middelen en behandelingen als preventie van arts-bioloog drs. engelbert Valstar.

21 november 2020: JAMA online 18 november 2020

Vitamine D-suppletie geeft een vermindering van het ontstaan van gevorderde uitgezaaide vormen van kanker. De sterkste afname werd waargenomen bij mensen met een normaal gewicht, volgens een studie die online is gepubliceerd op 18 november online bij JAMA Network Open.

Paulette D. Chandler, MD, MPH, van de Harvard Medical School in Boston, en collega's hebben een follow-up uitgevoerd naar de mogelijke vermindering van het aantal sterfgevallen door kanker die werd gezien in de vitamine D- en omega-3-studie (zie dit artikel) om te onderzoeken of vitamine D de incidentie van gevorderde kanker verminderde en mogelijke beïnvloeding door een body mass index (BMI). De primaire uitkomst voor deze analyse was een samengestelde incidentie van uitgezaaide en fatale invasieve vormen van kanker.

De onderzoekers ontdekten dat deelnemers die willekeurig werden toegewezen aan of vitamine D of een placebo een statistisch significante vermindering van gevorderde vormen van kanker hadden bij de dianose (uitgezaaid of fataal); 1,7 procent van de 12.927 patiënten uit de vitamine D groep hadden een uitgezaaide vorm van kanker of overlden aan hun kanker, versus 2,1 procent van de 12.944 patiënten uit de placebogroep; hazard ratio, 0,83) .

Bij stratificatie op basis van het BMI werd de afname van incidentele uitgezaaide of fatale kanker gezien voor de vitamine D groep onder degenen met een normale BMI (BMI <25 kg / m2: hazard ratio, 0,62), maar niet statistisch significant bij degenen met overgewicht of obesitas.

Uit het studierapport:

Findings In this secondary analysis of a randomized clinical trial with 25 871 patients, supplementation with vitamin D₃ reduced the incidence of advanced (metastatic or fatal) cancer in the overall cohort, with strongest risk reduction in individuals with normal weight and no reduction among individuals with overweight or obesity.

Het studierapport is gratis in te zien in JAMA online, hier het abstract van de studie:

November 18, 2020

Effect of Vitamin D₃ Supplements on Development of Advanced CancerA Secondary Analysis of the VITAL Randomized Clinical Trial

Paulette D. Chandler, MD, MPH¹; Wendy Y. Chen, MD, MPH^2,3; Oluremi N. Ajala, MD, MPH¹; et alAditi Hazra, PhD, MPH¹; Nancy Cook, ScD¹; Vadim Bubes, PhD¹; I-Min Lee, MBBS, ScD¹; Edward L. Giovannucci, MD, ScD^3,4,5; Walter Willett, MD, DrPH^3,4,5; Julie E. Buring, ScD^1,5; JoAnn E. Manson, MD, DrPH^1,3,5; for the VITAL Research Group

Author Affiliations Article Information

JAMA Netw Open. 2020;3(11):e2025850. doi:10.1001/jamanetworkopen.2020.25850

Key Points

Question Does vitamin D₃ supplementation reduce the risk of developing advanced (metastatic or fatal) cancer among adults without a diagnosis of cancer at baseline?

Meaning These findings suggest that vitamin D₃ may reduce the risk of developing advanced cancer among adults without a diagnosis of cancer at baseline; this protective effect is apparent for those who have normal but not elevated body mass index.

Abstract

Importance Epidemiologic and trial data suggest that vitamin D supplementation may reduce metastatic cancer and cancer mortality, reflecting shared biological pathways.

Objective To follow up on the possible reduction in cancer death in the Vitamin D and Omega-3 Trial (VITAL) with an evaluation of whether vitamin D reduces the incidence of advanced (metastatic or fatal) cancer and an examination possible effect modification by body mass index.

Design, Setting, and Participants VITAL is a randomized, double-blind, placebo-controlled, 2 × 2 factorial clinical trial of vitamin D₃ (cholecalciferol, 2000 IU/d) and marine omega-3 fatty acids (1 g/d). This multicenter clinical trial was conducted in the United States; participants included men aged 50 years or older and women aged 55 years or older who were free of cancer and cardiovascular disease at baseline. Randomization took place from November 2011 through March 2014, and study medication ended on December 31, 2017. Data for this secondary analysis were analyzed from November 1, 2011, to December 31, 2017.

Interventions Vitamin D₃ (cholecalciferol, 2000 IU/d) and marine omega-3 fatty acids (1 g/d) supplements.

Main Outcomes and Measures For the present analysis, the primary outcome was a composite incidence of metastatic and fatal invasive total cancer, because the main VITAL study showed a possible reduction in fatal cancer with vitamin D supplementation and effect modification by body mass index (BMI; calculated as weight in kilograms divided by height in meters squared) for total cancer incidence reduction for individuals with normal BMI, but not for individuals with overweight or obesity. Secondary analyses included examination of BMI (<25, 25 to < 30, and ≥30) as effect modifiers of the observed associations.

Results Among 25 871 randomized VITAL participants (51% female; mean age, 67.1 [7.1] years), 1617 were diagnosed with invasive cancer over a median intervention period of 5.3 years (range, 3.8-6.1 years). As previously reported, no significant differences for cancer incidence by treatment arm were observed. However, a significant reduction in advanced cancers (metastatic or fatal) was found for those randomized to vitamin D compared with placebo (226 of 12 927 assigned to vitamin D [1.7%] and 274 of 12 944 assigned to placebo [2.1%]; HR, 0.83 [95% CI, 0.69-0.99]; P = .04). When stratified by BMI, there was a significant reduction for the vitamin D arm in incident metastatic or fatal cancer among those with normal BMI (BMI<25: HR, 0.62 [95% CI, 0.45-0.86]) but not among those with overweight or obesity (BMI 25-<30: HR, 0.89 [95% CI, 0.68-1.17]; BMI≥30: HR, 1.05 [95% CI, 0.74-1.49]) (P = .03 for interaction by BMI).

Conclusions and Relevance In this randomized clinical trial, supplementation with vitamin D reduced the incidence of advanced (metastatic or fatal) cancer in the overall cohort, with the strongest risk reduction seen in individuals with normal weight.

Trial Registration ClinicalTrials.gov Identifier: NCT01169259

References

Keum N, Lee DH, Greenwood DC, Manson JE, Giovannucci E. Vitamin D supplementation and total cancer incidence and mortality: a meta-analysis of randomized controlled trials. Ann Oncol. 2019;30(5):733-743. doi:10.1093/annonc/mdz059 PubMed Google Scholar Crossref

Zhang Y, Fang F, Tang J, et al. Association between vitamin D supplementation and mortality: systematic review and meta-analysis. BMJ. 2019;366:l4673. doi:10.1136/bmj.l4673 PubMed Google Scholar Crossref

Feldman D, Krishnan AV, Swami S, Giovannucci E, Feldman BJ. The role of vitamin D in reducing cancer risk and progression. Nat Rev Cancer. 2014;14(5):342-357. doi:10.1038/nrc3691 PubMed Google Scholar Crossref

Institute of Medicine Committee to Review Dietary Reference Intakes for Vitamin D and Calcium. Ross AC, Taylor CL, Yaktine AL, Del Valle HB, eds. Dietary Reference Intakes for Calcium and Vitamin D. Washington, DC: National Academies Press; 2011.

Keum N, Giovannucci E. Vitamin D supplements and cancer incidence and mortality: a meta-analysis. Br J Cancer. 2014;111(5):976-980. doi:10.1038/bjc.2014.294 PubMed Google Scholar Crossref

Manson JE, Cook NR, Lee IM, et al; VITAL Research Group. Vitamin D supplements and prevention of cancer and cardiovascular disease. N Engl J Med. 2019;380(1):33-44. doi:10.1056/NEJMoa1809944 PubMed Google Scholar Crossref

Martineau AR, Jolliffe DA, Hooper RL, et al. Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data. BMJ. 2017;356:i6583. doi:10.1136/bmj.i6583 PubMed Google Scholar Crossref

Formenti AM, Tecilazich F, Frara S, Giubbini R, De Luca H, Giustina A. Body mass index predicts resistance to active vitamin D in patients with hypoparathyroidism. Endocrine. 2019;66(3):699-700. doi:10.1007/s12020-019-02105-6 PubMed Google Scholar Crossref

Guzik TJ, Skiba DS, Touyz RM, Harrison DG. The role of infiltrating immune cells in dysfunctional adipose tissue. Cardiovasc Res. 2017;113(9):1009-1023. doi:10.1093/cvr/cvx108 PubMed Google Scholar Crossref

10.

Martí A, Marcos A, Martínez JA. Obesity and immune function relationships. Obes Rev. 2001;2(2):131-140. doi:10.1046/j.1467-789x.2001.00025.x PubMed Google Scholar Crossref

11.

Bähr I, Jahn J, Zipprich A, Pahlow I, Spielmann J, Kielstein H. Impaired natural killer cell subset phenotypes in human obesity. Immunol Res. 2018;66(2):234-244. doi:10.1007/s12026-018-8989-4 PubMed Google Scholar Crossref

12.

Lee GY, Park CY, Cha KS, Lee SE, Pae M, Han SN. Differential effect of dietary vitamin D supplementation on natural killer cell activity in lean and obese mice. J Nutr Biochem. 2018;55:178-184. doi:10.1016/j.jnutbio.2018.01.004 PubMed Google Scholar Crossref

13.

Woodall MJ, Neumann S, Campbell K, Pattison ST, Young SL. The effects of obesity on anti-cancer immunity and cancer immunotherapy. Cancers (Basel). 2020;12(5):E1230. doi:10.3390/cancers12051230 PubMed Google Scholar

14.

Cuyàs E, Verdura S, Martin-Castillo B, et al. Tumor cell-intrinsic immunometabolism and precision nutrition in cancer immunotherapy. Cancers (Basel). 2020;12(7):E1757. doi:10.3390/cancers12071757 PubMed Google Scholar

15.

Wang Z, Aguilar EG, Luna JI, et al. Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade. Nat Med. 2019;25(1):141-151. doi:10.1038/s41591-018-0221-5 PubMed Google Scholar Crossref

16.

Abbas MA. Physiological functions of Vitamin D in adipose tissue. J Steroid Biochem Mol Biol. 2017;165(Pt B):369-381. doi:10.1016/j.jsbmb.2016.08.004 Google Scholar

17.

Schulz KF, Altman DG, Moher D, CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Ann Intern Med. 2010;152(11):726-732. doi:10.7326/0003-4819-152-11-201006010-00232 PubMed Google Scholar Crossref

18.

Fritz AG, Percy C, Jack A, et al International Classification of Diseases for Oncology (ICD-O), Third Edition. Geneva: World Health Organization; 2000.

19.

Ng K, Nimeiri HS, McCleary NJ, et al. Effect of high-dose vs standard-dose vitamin D3 supplementation on progression-free survival among patients with advanced or metastatic colorectal cancer: the SUNSHINE randomized clinical trial. JAMA. 2019;321(14):1370-1379. doi:10.1001/jama.2019.2402
Article PubMed Google Scholar Crossref

20.

Urashima M, Ohdaira H, Akutsu T, et al. Effect of vitamin D supplementation on relapse-free survival among patients with digestive tract cancers: the AMATERASU randomized clinical trial. JAMA. 2019;321(14):1361-1369. doi:10.1001/jama.2019.2210
Article PubMed Google Scholar Crossref

21.

Díaz GD, Paraskeva C, Thomas MG, Binderup L, Hague A. Apoptosis is induced by the active metabolite of vitamin D3 and its analogue EB1089 in colorectal adenoma and carcinoma cells: possible implications for prevention and therapy. Cancer Res. 2000;60(8):2304-2312.PubMed Google Scholar

22.

Scaglione-Sewell BA, Bissonnette M, Skarosi S, Abraham C, Brasitus TA. A vitamin D3 analog induces a G1-phase arrest in CaCo-2 cells by inhibiting cdk2 and cdk6: roles of cyclin E, p21Waf1, and p27Kip1. Endocrinology. 2000;141(11):3931-3939. doi:10.1210/endo.141.11.7782 PubMed Google Scholar Crossref

23.

Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357(3):266-281. doi:10.1056/NEJMra070553 PubMed Google Scholar Crossref

24.

Han J, Guo X, Yu X, et al. 25-hydroxyvitamin D and total cancer incidence and mortality: a meta-analysis of prospective cohort studies. Nutrients. 2019;11(10):E2295. doi:10.3390/nu11102295 PubMed Google Scholar

25.

Yuan C, Sato K, Hollis BW, et al. Plasma 25-hydroxyvitamin D levels and survival in patients with advanced or metastatic colorectal cancer: findings from CALGB/SWOG 80405 (Alliance). Clin Cancer Res. 2019;25(24):7497-7505. doi:10.1158/1078-0432.CCR-19-0877

26.

Kennel KA, Drake MT. Vitamin D in the cancer patient. Curr Opin Support Palliat Care. 2013;7(3):272-277. doi:10.1097/SPC.0b013e3283640f74 PubMed Google Scholar Crossref

27.

Alkan A, Köksoy EB. Vitamin D deficiency in cancer patients and predictors for screening (D-ONC study). Curr Probl Cancer. 2019;43(5):421-428. doi:10.1016/j.currproblcancer.2018.12.008 PubMed Google Scholar Crossref

28.

Jung YS, Wu D, Smith D, Meydani SN, Han SN. Dysregulated 1,25-dihydroxyvitamin D levels in high-fat diet-induced obesity can be restored by changing to a lower-fat diet in mice. Nutr Res. 2018;53:51-60. doi:10.1016/j.nutres.2018.03.008 PubMed Google Scholar Crossref

29.

Wortsman J, Matsuoka LY, Chen TC, Lu Z, Holick MF. Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr. 2000;72(3):690-693. doi:10.1093/ajcn/72.3.690 PubMed Google Scholar Crossref

30.

Drincic AT, Armas LA, Van Diest EE, Heaney RP. Volumetric dilution, rather than sequestration best explains the low vitamin D status of obesity. Obesity (Silver Spring). 2012;20(7):1444-1448. doi:10.1038/oby.2011.404 PubMed Google Scholar Crossref

31.

Kim H, Chandler P, Ng K, Manson JE, Giovannucci E. Obesity and efficacy of vitamin D₃ supplementation in healthy black adults. Cancer Causes Control. 2020;31(4):303-307. doi:10.1007/s10552-020-01275-3 PubMed Google Scholar Crossref

32.

Moslehi N, Shab-Bidar S, Mirmiran P, Hosseinpanah F, Azizi F. Determinants of parathyroid hormone response to vitamin D supplementation: a systematic review and meta-analysis of randomised controlled trials. Br J Nutr. 2015;114(9):1360-1374. doi:10.1017/S0007114515003189 PubMed Google Scholar Crossref

33.

Lotito A, Teramoto M, Cheung M, Becker K, Sukumar D. Serum parathyroid hormone responses to vitamin D supplementation in overweight/obese adults: a systematic review and meta-analysis of randomized clinical trials. Nutrients. 2017;9(3):E241. doi:10.3390/nu9030241 PubMed Google Scholar

34.

Rothwell PM, Cook NR, Gaziano JM, et al. Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials. Lancet. 2018;392(10145):387-399. doi:10.1016/S0140-6736(18)31133-4 PubMed Google Scholar Crossref

35.

Bassuk SS, Manson JE, Lee IM, et al. Baseline characteristics of participants in the VITamin D and OmegA-3 TriaL (VITAL). Contemp Clin Trials. 2016;47:235-243. doi:10.1016/j.cct.2015.12.022 PubMed Google Scholar Crossref

36.

Haidari F, Abiri B, Iravani M, et al. Effects of vitamin D and omega-3 fatty acids co-supplementation on inflammatory biomarkers, tumor marker CEA, and nutritional status in patients with colorectal cancer: a study protocol for a double blind randomized controlled trial. Trials. 2019;20(1):682. doi:10.1186/s13063-019-3719-3 PubMed Google Scholar Crossref

preventie, vitamin D3 (cholecalciferol, 2000 IU/d), visolie, uitgezaaide vormen van kanker, obese, BMI, JAMA, placebo gecontroleerde studie